Researchers are investigating whether a groundbreaking cancer treatment known as CAR-T cell therapy can be repurposed to treat severe cases of multiple sclerosis (MS). Early-phase clinical trials, reported in journals like Science Immunology and The Lancet Neurology, have shown that the therapy can deplete the body's B cells, which are implicated in the autoimmune attack on the nervous system in MS.
In these small studies, patients with aggressive, treatment-resistant forms of MS experienced a halt in disease progression and a significant reduction in brain lesions after receiving CAR-T therapy. The treatment, which involves genetically engineering a patient's own T cells to target specific proteins, appears to offer a deep and prolonged reset of the immune system.
However, experts emphasize these are early results. The therapy carries significant risks, including severe side effects like cytokine release syndrome and prolonged vulnerability to infections due to B-cell depletion. Larger, long-term controlled trials are necessary to confirm its safety and efficacy for MS before it could become a standard treatment option.
The research represents a significant shift in exploring powerful immunotherapies for autoimmune diseases. While not a cure, CAR-T therapy offers a potential new avenue for patients with highly active MS who have not responded to existing medications.
